The 2026 EIC Accelerator introduces major changes that raise the bar for life sciences innovators, including €414 million for open calls, a doubled minimum equity investment of €1 million, and a mandatory TRL 5 threshold. These shifts prioritise later-stage companies with proven commercial traction and committed co-investors. While competition will become tougher, the programme remains Europe’s most powerful source of non-dilutive funding, offering recipients both substantial financial support and the prestigious EIC endorsement—a catalyst for 2–3x follow-on investment and accelerated partnerships or exits within 2–3 years.

Our team understands exactly what EIC evaluators and investors seek. Contact us to discuss your EIC Accelerator strategy. In this episode, Dr Caroline Chauché explains what’s changed in 2026 and why it matters for life sciences innovations”